STOCK TITAN

MacroGenics to Participate in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. The management will engage in a fireside chat on May 20, 2021, at 9:20 am ET. A webcast of the event can be accessed on the Company’s Investor Relations page. MacroGenics focuses on developing monoclonal antibody-based therapeutics for cancer treatment, leveraging innovative technology platforms and strategic collaborations for its product pipeline.

Positive
  • None.
Negative
  • None.

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) --  

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. MacroGenics’ management will participate in a fireside chat with the analyst on Thursday, May 20, 2021, at 9:20 am ET.

A webcast of the fireside chat may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company maintains archived replays of webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###


FAQ

When is MacroGenics participating in the Oncology Innovation Summit?

MacroGenics will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 9:20 am ET.

Where can I watch the MacroGenics fireside chat?

You can watch the MacroGenics fireside chat on the Company's Investor Relations page under 'Events & Presentations'.

What does MacroGenics focus on?

MacroGenics focuses on developing and commercializing monoclonal antibody-based therapeutics for cancer treatment.

What is the stock symbol for MacroGenics?

The stock symbol for MacroGenics is MGNX.

How does MacroGenics develop its product pipeline?

MacroGenics generates its product pipeline through proprietary antibody-based technology platforms and strategic collaborations.

MacroGenics, Inc.

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

204.61M
58.33M
2.64%
93.68%
8.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
Rockville